Effectiveness of nurse delivered endoscopy: findings from randomised multi-institution nurse endoscopy trial (MINuET) by Williams, John et al.
RESEARCH
Effectiveness of nurse delivered endoscopy: findings
from randomised multi-institution nurse endoscopy trial
(MINuET)
John Williams,1 Ian Russell,2 Dharmaraj Durai,3 Wai Yee Cheung,1 Amanda Farrin,4 Karen Bloor,5
Simon Coulton,6 Gerry Richardson7
ABSTRACT
Objective To compare the clinical effectiveness of doctors
and nurses in undertaking upper and lower
gastrointestinal endoscopy.
Design Pragmatic trial with Zelen’s randomisation before
consent to minimise distortion of existing practice.
Setting 23 hospitals in the United Kingdom. In six
hospitals, nurses undertook both upper and lower
gastrointestinal endoscopy, yielding a total of 29 centres.
Participants 67 doctors and 30 nurses. Of 4964
potentially eligible patients, we randomised 4128 (83%)
and recruited 1888 (38%) from July 2002 to June 2003.
Interventions Diagnostic upper gastrointestinal
endoscopy and flexible sigmoidoscopy, undertaken with
or without sedation, with the standard preparation,
techniques, and protocols of participating hospitals. After
referral for either procedure, patients were randomised
between doctors and nurses.
Main outcomemeasuresGastrointestinal symptom rating
questionnaire (primary outcome), gastrointestinal
endoscopy satisfaction questionnaire and state-trait
anxiety inventory (all analysed by intention to treat);
immediate and delayed complications; quality of
examination and corresponding report; patients’
preferences for operator; and new diagnoses at one year
(all analysed according to who carried out the procedure).
Results There was no significant difference between
groups inoutcomeatoneday, onemonth, or one year after
endoscopy, except that patients were more satisfied with
nurses after one day. Nurses were also more thorough
than doctors in examining the stomach and oesophagus.
While quality of life scores were slightly better in patients
in the doctor group, this was not statistically significant.
Conclusions Diagnostic endoscopy can be undertaken
safely and effectively by nurses.
Trial registration International standard RCT 82765705.
INTRODUCTION
In the United Kingdom and the United States, gastro-
intestinal endoscopy is increasingly being carried out
by nurses,1 2 with approval from professional bodies.3 4
Single centre studies have suggested that this is safe,
effective, and acceptable to patients in both
countries.5-11 There has, however, been no rigorous,
large scale evaluation of the clinical and cost effective-
ness of nurses in this role.
METHODS
Study design and interventions
Our study12 was a pragmatic randomised trial13
designed to compare gastrointestinal endoscopy
undertaken by doctors or nurses using the standard
procedure of participating hospitals.
Recruitment
We invited hospitals in theUKwith nurses whowere
undertaking independent gastrointestinal endo-
scopy to participate in the study, through the British
Society of Gastroenterology (BSG) newsletter. We
included patients aged over 18 who had been
referred for oesophagogastroduodenoscopy or flex-
ible sigmoidoscopy with symptoms of dyspepsia,
weight loss, anorexia, anaemia, rectal bleeding, or
change in bowel habit. On receiving referrals for
either procedure—that is, before consent14—we
stratified patients by hospital and procedure and
randomly allocated them to endoscopy by doctor or
by nurse. We estimated the experience of endo-
scopists with a questionnaire completed before
participation.
Outcome measures and data collection
The primary outcome, measured at one year, was
patients’ self assessed scores on the gastrointestinal
symptom rating questionnaire.12 Secondary outcomes
included scoreson the symptomratingquestionnaireat
one month and the state-trait anxiety inventory,15
SF-36,16 and EQ-5D,17 all measured at baseline,
one day, one month, and one year after the procedure.
We measured patients’ satisfaction after one day
using the gastrointestinal endoscopy satisfaction
questionnaire.12
We compared operators’ performance by analysing
endoscopic video recordings using developed and
validated measurement scales, and extracting data
from clinical records. We also compared endoscopy
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reports with the British Society of Gastroenterology’s
standards.18 We extracted final diagnosis, incidence of
late complications, new diagnoses, and subsequent
contact with health professionals fromhospital records
after one year.
Analysis
We analysed participants’ outcomes by intention to
endoscope. Logistic regression tested the symptom
rating score at one year for differences between groups
after adjusting for covariates. We estimated mean
differences between groups in one year symptom
rating scores, and state-trait anxiety inventory, SF-36,
and EQ-5D scores by analysis of covariance. We
undertook a sensitivity analysis by excluding centres
where large numbers of patients changed endoscopist
after randomisation.
RESULTS
Endoscopist recruitment
Twenty three hospitals participated, of which three
recruited patients only for oesophagogastroduodeno-
scopy, 14 only for flexible sigmoidoscopy, and six for
both.Hospitals recruitedparticipants fromJuly2002 to
June 2003. Sixty seven doctors and 30 nurses took part,
all of whom were fully trained to practise endoscopy
independently. There was no difference between the
two groups in their routine practice before and after
endoscopy.
Recruitment and follow-up of participants
Of the 4964 patients referred for either flexible
sigmoidoscopy or oesophagogastroduodenoscopy,
4128 were randomised before consent. Of these,
3133 (76%) attended the appointment and 1888
(46%) gave consent to participate in the trial. The
characteristics of the randomised patients who did not
take part in the trial were not significantly different
from thosewho did. The two study groupswere similar
in age, sex, type of access, and presenting symptoms
(see bmj.com).
The outcome questionnaire was completed by 1782
(94%) patients at baseline, 1536 (81%) at one day, 1427
(76%) at one month, and 1333 (71%) at one year.
Patients’ outcomes
Table 1 shows that, after adjustment for baseline score,
hospital, type of procedure, and age with analysis of
covariance, there was no significant difference between
the two groups on any of the four factors on the
gastrointestinal symptomratingquestionnaireatoneyear.
After adjustment for baseline SF-36 score, hospital,
type of procedure, and age with analysis of covariance,
there was no significant difference between the two
groups on any of the eight subscales or two summary
scores of the SF-36 at one day or one month. At one
year there was a significant improvement in social
functioning in favour of doctors. Given that the SF-36
gave rise to 24 significance tests, however, this does not
provide prima facie evidence of differences between
groups.
After adjustment for baseline anxiety, hospital, type
of procedure, andagewith analysis of covariance, there
was no significant difference in anxiety levels between
the two groups at any point (table 2). There was a
significant difference in patients’ satisfaction after
endoscopy in favour of nurses on all four factors of
the gastrointestinal endoscopy satisfaction question-
naire (table 2).
We repeated our analyses after excluding the three
centres where more than 30 patients changed endo-
scopist. None of our conclusions was sensitive to this
change. We analysed findings about process and
performance by operator rather than intention to
scope. After one year we reviewed medical records
for 1674 patients (89% of the 1888 recruited). There
was no evidence that any major pathology had
been missed. There were no significant differences
in use of lidocaine spray or benzodiazepines for
Table 1 | Differences in primary outcome measure; figures are adjusted* mean scores (range 0 (no symptoms)-100) on
gastrointestinal (GI) symptom rating questionnaire
Doctor group Nurse group
Difference† (95% CI)No of patients Mean (SE) No of patients Mean (SE)
At one month
Factor 1: upper GI 675 12.6 (0.58) 701 13.8 (0.57) −1.20 (−2.33 to −0.080)
Factor 2: lower GI 675 25.0 (1.02) 698 24.3 (1.01) 0.77 (−1.21 to 2.75)
Factor 3: wind 677 34.4 (0.92) 703 35.3 (0.91) −0.87 (−2.66 to 0.92)
Factor 4: defecation 672 21.3 (0.90) 695 20.6 (0.88) 0.69 (−1.03 to 2.42)
At one year
Factor 1: upper GI 634 11.8 (0.69) 645 12.4 (0.70) −0.61 (−1.92 to 0.70)
Factor 2: lower GI 624 21.4 (1.16) 639 22.8 (1.17) −1.46 (−3.67 to 0.75)
Factor 3: wind 635 32.6 (1.06) 646 31.6 (1.07) 0.98 (−1.04 to 3.00)
Factor 4: defecation 623 18.7 (0.98) 639 19.9 (0.99) −1.23 (−3.10 to 0.64)
*Adjusted for baseline score, centre, type of procedure, and age with analysis of covariance.
†Difference for doctor minus nurse; thus negative difference indicates that patients in nurse group score worse on average than patients in doctor
group and positive difference indicates that patients in nurse group score better on average than patients in doctor group.
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oesophagogastroduodenoscopy, but nurses used the
combination significantly more often than doctors
(18% v 6%; P<0.001 by χ2 test).
There was no difference between the two groups in
the distance the endoscopewas inserted into the colon,
the mean duration of examination, the number of
immediate or delayed clinical complications, defects
identified in equipment, need for assistance during the
procedure, or diagnoses made. Results of upper
gastrointestinal endoscopies were reported as normal
by 30% of doctors and 18% of nurses (P<0.001 by χ2
test); the corresponding percentages for flexible
sigmoidoscopies were 45% and 34% (P<0.001 by χ2
test). More patients had biopsies in the nurse group
(50% v 31% by doctors for oesophagogastroduodeno-
scopy, P<0.001 by χ2 test; 35% v 27% by doctors for
flexible sigmoidoscopy; P=0.006).
Analysis of video recordings of oesophagogastro-
duodenoscopy showed significantly better (that is,
lower) scores by nurses in technique and thoroughness
for theoesophagus (mean23.7 (SD8.8) v28.7 (SD12.8)
for doctors; t=3.16, P=0.002) and stomach (43.7 (SD
13.8) v 54.2 (SD 20.3), t=4.16, P<0.001). There was no
significant difference in the corresponding scores for
the duodenum. For flexible sigmoidoscopy, there was
no significant difference in the rating of technical
performance between the two groups.
In 1784 endoscopy reports (760 by doctors; 1024 by
nurses) there was no significant difference in the
recording of most items, though type of episode,
urgency, sedation, free text comments, discharge, and
follow-up arrangements were recorded more consis-
tently and significantly better by nurses.
Complications
There were no recorded complications with the endo-
scope. There was no significant difference between the
number of immediate or delayed complications
identified after endoscopy by a doctor or a nurse.12
DISCUSSION
Principal findings
We found little significant difference in the clinical
outcomes of diagnostic endoscopy performed by
doctors or nurses, as reported by participants at one
day, onemonth, and one year after procedure. Patients
were significantly more satisfied with nurses one day
after the procedure. Nurses weremore thorough in the
examination of stomach and oesophagus, carried out
more biopsies than doctors, and omitted fewer items
from reports.
Strengths and weaknesses of trial
Our pragmatic trial compared endoscopy by nurses
and doctors operating in their usual environment with
their usual working practices. We used Zelen’s design
of randomisation before consent. Not surprisingly
many potential participants left after randomisation.
Nevertheless, we recruited 1888 (60%) of the 3133
eligible patients who attended for the procedure
after randomisation. Furthermore, proportions
recruited were similar in both groups, and the
characteristics of those recruited were representative
of those randomised.
We assessed patients recruited on the basis of
symptoms reported before diagnosis. We found no
validated instrument to do this and so developed a
system specific gastrointestinal symptom rating ques-
tionnaire. We followed established practice by devel-
oping the questionnaire clinically, then testing it on
patients with known disorders, and finally validating it
on a large clinical sample.19
Our results showed that the gastrointestinal symp-
tom rating questionnaire is a valid questionnaire for
assessing gastrointestinal symptoms.12 We assessed
86% of the endoscopy procedures using objective
measures. Response rates were acceptable for a
pragmatic trial, and similar in the two groups. The
low incidence of new diagnoses did not differ between
the two groups. We believe it unlikely that longer
Table 2 | Differences in secondary outcome measures, state-trait anxiety, and GESQ
Doctor Nurse
Difference‡
(95% CI)
No of
patients*
Adjusted†mean
(SE) score
No of
patients*
Adjusted†mean
(SE) score
State-trait anxiety inventory, state anxiety§
One day 667 38.6 (0.45) 703 39.0 (0.44) 0.33 (−0.57 to 1.23)
One month 634 37.7 (0.54) 645 37.9 (0.53) 0.15 (−0.89 to 1.20)
One year 599 38.3 (0.61) 594 38.8 (0.61) 0.56 (−0.60 to 1.72)
GESQ¶ at one day
Skills and hospital 619 14.5 (0.46) 710 12.0 (0.42) 2.57 (1.35 to 3.79)
Pain and discomfort 622 33.6 (0.80) 710 30.3 (0.75) 3.35 (1.19 to 5.50)
Information before endoscopy 623 21.2 (0.54) 716 18.3 (0.55) 2.97 (1.45 to 4.48)
Information after endoscopy 517 22.0 (0.88) 633 17.1 (0.79) 4.84 (2.53 to 7.15)
*Maximum number 737 for doctor group and 789 for nurse group.
†Adjusted for baseline score, centre, type of procedure, and age using analysis of covariance.
‡Difference for score with doctor minus score with nurse, thus negative difference indicates that patients in nurse group score worse on average than
patients in doctor group and positive difference indicates that patients in nurse group score better on average than patients in doctor group.
§Range 20 (high anxiety)-80.15
¶Range 0 (satisfied)-100.12
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follow-up would have yielded further findings after
oesophagogastroduodenoscopy.
Participating hospitals included large and small,
urban and rural, and teaching and non-teaching. Thus
trial recruitment reflectedvariations in theorganisation
of endoscopy services across the UK and a wide
spectrum of common indications. The number of
trained nurse endoscopists has increased since the trial,
but we judge that those who participated were
representative of the growing expertise in endoscopy
in the UK. The trial shows how the performance of the
typically femalebut formally trainednurse endoscopist
compares with that of the typically male medical
endoscopist who learnt through apprenticeship.
Strengths and weaknesses in relation to other studies
These findings reinforce results of single centre studies
suggesting that nurses can safely and effectively carry
out flexible sigmoidoscopy.5-8We have confirmed that
quality of life improves after endoscopy by both
doctors and nurses.20 We have also confirmed the
findings of a single centre trial that nurses are as
competent as doctors in examining the upper gastro-
intestinal tract.21
Unanswered questions
Our economic evaluation suggests that doctors are
likely to be more cost effective than nurses in the
current state of their training and experience.22
Planners need to consider the relative clinical effec-
tiveness and cost effectiveness for endoscopy services
of the two professions. They also need to consider the
availability of potential staff. As nurses grow in
experience over time, it will be important to continue
to monitor effectiveness and cost effectiveness.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Nurses are increasingly undertaking both upper and lower
gastrointestinal endoscopy
Single centre studies suggest that nurse endoscopists are
competent and are appreciated by patients
WHAT THIS STUDY ADDS
There is no significant difference between doctors and
nurses in their clinicaleffectiveness indiagnosticendoscopy
Nursesaremore thoroughthandoctors inexaminationof the
oesophagus and stomach
Patients are more satisfied after an endoscopy by a nurse
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Cost effectiveness of nurse delivered endoscopy: findings
from randomised multi-institution nurse endoscopy trial
(MINuET)
Gerry Richardson,1 Karen Bloor,2 John Williams,3 Ian Russell,4 Dharmaraj Durai,5 Wai Yee Cheung,3
Amanda Farrin,6 Simon Coulton7
ABSTRACT
Objective To compare the cost effectiveness of nurses and
doctors in performing upper gastrointestinal endoscopy
and flexible sigmoidoscopy.
Design As part of a pragmatic randomised trial, the
economic analysis calculated incremental cost
effectiveness ratios, and generated cost effectiveness
acceptability curves to address uncertainty.
Setting 23 hospitals in the United Kingdom.
Participants 67 doctors and 30 nurses, with a total of
1888 patients, from July 2002 to June 2003.
InterventionDiagnosticupper gastrointestinal endoscopy
and flexible sigmoidoscopy carried out by doctors or
nurses.
Main outcomemeasures Estimated health gains in QALYs
measured with EQ-5D. Probability of cost effectiveness
over a range of decision makers’ willingness to pay for an
additional quality adjusted life year (QALY).
Results Although differences did not reach traditional
levels of significance, patients in the doctor group gained
0.015 QALYs more than those in the nurse group, at an
increased cost of about £56 (€59, $78) per patient. This
yields an incremental cost effectiveness ratio of £3660
(€3876, $5097) per QALY. Though there is uncertainty
around these results, doctors are probably more cost
effective than nurses for plausible values of a QALY.
Conclusions Though upper gastrointestinal endoscopies
and flexible sigmoidoscopies carried out by doctors cost
slightly more than those by nurses and improved health
outcomes only slightly, our analysis favours endoscopies
by doctors. For plausible values of decision makers’
willingness to pay for an extra QALY, endoscopy delivered
by nurses is unlikely to be cost effective compared with
endoscopy delivered by doctors.
Trial registration International standard RCT 82765705.
INTRODUCTION
Endoscopy is becoming widely practised by nurses in
the United Kingdom.1 There has been little evaluation
of the cost effectiveness of procedures undertaken by
nurses rather than by doctors.
Economic evaluations of screening tests often
estimate a “cost per condition detected”. We focused
not on the cost effectiveness of endoscopy itself but on
whether or not there is a difference in endoscopy
delivered by doctors or nurses. We assessed relative
cost effectiveness as part of a pragmatic randomised
controlled trial undertaken in the UK.2
METHODS
Study design and interventions
The clinical study was a pragmatic randomised trial in
23 hospitals in the UK.3 A total of 1888 patients were
randomised to either a doctor or a nurse for upper
gastrointestinal endoscopy or flexible sigmoidoscopy.
Wecollectedhealth outcomemeasures at baseline, one
day, one month, and one year after the intervention.
We take a UK National Health Service (NHS)
perspective with effects assessed in terms of health
gains measured in QALYs.
Data collection and outcome measures
We extracted information on resources used during
endoscopy from resource time sheets. Information
included duration of endoscopy, number of patients
undergoing endoscopy, staffing, and consumables used.
We obtained data on resource use after the endo-
scopy from examination of patients’ medical records
and patients’ questionnaires administered at baseline
and 12 months. We estimated the cost of the inter-
vention fromdata on the duration of intervention from
the clinical trial multiplied by estimated costs per
minute in 2002-3 prices.4
The EQ-5D instrument5 measured patients’ health
states across five dimensions (mobility, self care, usual
activities, pain and discomfort, and anxiety and
depression) and ascribes values to those states.
WeconvertedallEQ-5Dscores to “utilities” througha
tariff derived from a representative UK population
sample.6 We compared mean QALYs generated in the
two groups over the 12month period.We plotted utility
at baseline and subsequentpoints andcalculated the area
under the curve to estimate QALYs gained by each
patient,7 adjusting these estimates for baseline EQ-5D
and including sex and age as covariates. In a subgroup
analysis we separately considered the cost effectiveness
of sigmoidoscopy and oesophagogastroduodenoscopy.
Analysis
Wecalculatednetmonetarybenefit8 for eachgroup.To
calculate patient specific net monetary benefits we
multiplied each patient’s QALYs by the assumed
maximum value of a QALY and subtracted that
patient’s costs. We used these patient specific net
monetary benefits to derive cost effectiveness accept-
ability curves and estimated the aggregate net benefit.
We used uncertainty around the net monetary
benefit to estimate the probability that a strategy is
cost effective through the cost effectiveness
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acceptability curve. This is a graphical representation
of theprobability of an interventionbeing cost effective
over a monetary range for a decision maker’s will-
ingness to pay for an additional unit of health gain.
RESULTS
Resource use
Endoscopy by nurses was followed by slightly more
use of all primary care resources except home visits
from general practitioners. In secondary care there
were increased attendances at day hospital and out-
patient clinics. These differences were small, however,
and did not reach significance.
Health states
Therewas littleeffect ineithergrouponusualactivitiesor
self care.Bothgroups showedan increasedproportionof
patients in the least severe pain and discomfort and
anxiety and depression groups, and these differences
favoured endoscopy delivered by doctors. Mobility
deteriorated in both groups, with the nurse group again
performing slightly less well than the doctor group.
QALYs
We estimated changes in EQ-5D over one year (table).
We used these estimates to generate QALYs. Though
differences were small, the gain in QALYs was greater
after endoscopy by doctors than by nurses. Adjustment
for EQ-5D score at baseline reduced the difference in
QALYs to 0.0153 (95% confidence interval −0.008 to
0.039) (table). We used this estimate in the construction
of cost effectiveness acceptability curves, which reflect
the finding that EQ-5D score at baseline was higher for
the doctor group.
While this difference in QALYs seems to be small in
absolute terms, it equates to a difference of five to six
days of additional perfect health each year. The most
likely explanation for this difference is that nurses
requested more subsequent tests that might have a
negative effect on patients’ wellbeing.
Total cost
The table shows estimated differences in cost per
patient between groups, including the cost of the
intervention. As there was uncertainty around these
estimates, the difference was not significant. The
intervention cost more in the doctor group because
doctors’ time costs more than nurses’ time. There was
little difference in the duration of endoscopy between
groups.Patients allocated todoctors had slightlyhigher
costs in both primary and secondary care.
Incremental cost effectiveness ratio (ICER)
Thedoctor group generated 0.0153moreQALYs than
the nurse group, at a net cost of £56 per patient. This
resulted in an incremental cost effectiveness ratio of
£3660perQALY.Thedifference inpatients’outcomes
and costs did not approach significance.
Net monetary benefits and cost effectiveness
acceptability curves
The figure shows the cost effectiveness acceptability
curve for values of a QALY between zero and £50000.
Attaching no value to a QALY yields a probability of
78% that nurses reduced costs. The probability of nurses
being cost effective, however, decreases as the value of a
QALY increases and as doctors become more cost
effective.At avalueof£30000perQALY,often stated to
be the borderline for the NHS, nurses have only a 13%
chance of being cost effective. There is, however, much
uncertainty around this result (see cost effectiveness
scatter on bmj.com).
Sigmoidoscopy v oesophagogastroduodenoscopy
For doctors sigmoidoscopy showed an incremental
cost effectiveness ratio of £2600 per QALY.
Mean EQ-5D scores, QALYs, and costs (£) per patient over 12 months by group
Doctor group (n=931) Nurse group (n=957) Difference (95% CI)
Mean EQ-5D scores:
Baseline 0.700 0.689 0.011 (−0.014 to 0.040)
One month 0.713 0.697 0.016 (−0.009 to 0.041)
One year 0.710 0.693 0.017 (−0.008 to 0.043)
QALYs 0.712 0.695 0.0153* (−0.008 to 0.039)
Primary care costs 135 128 7 (−3 to 15)
Secondary care costs 565 538 27 (−127 to 181)
Intervention costs 39 16 23 (20 to 26)
Total cost 739 683 56 (−100 to 213)
*Difference in QALYs allows for baseline differences in EQ-5D, sex, and age.
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Oesophagogastroduodenoscopy cost relatively more,
resulting in a higher ratio of £7850. Both ratios would
be acceptable for most reasonable values of a decision
maker’s willingness to pay for a QALY.
DISCUSSION
Principal findings
Patients undergoing endoscopy carried out by doctors
gained 0.015 QALYs more than those treated by
nurses, at an increased cost of around £56 per patient,
yielding an incremental cost effectiveness ratio of
£3660 per QALY. Endoscopy delivered by nurses is
unlikely to be cost effective compared with endoscopy
delivered by doctors based on the evidence of this
single trial analysis. There is considerable uncertainty
around these estimates, which indicates that further
research is needed.
Strengths and weaknesses
We used a randomised trial to compare the cost
effectiveness of doctors and nurses performing endo-
scopy. The study lasted only one year, though there is
potential for later effects in this population. However,
the similarity of immediate and delayed complications
between nurses and doctors suggests there is little
difference in their long term performance.
It is possible that the use of the EQ-5D and the
resulting estimates of QALYs are not sensitive enough
in these patients to identify differences in their health
related quality of life. The results of our economic
analysis, however, are similar to those of the clinical
analysis in that there was a non-significant effect in
favour of doctors.
As nurses’ experience and confidence grows, they
might becomemore confident and order fewer follow-
up tests. The higher frequency of tests and inter-
ventions in the nurse group, however, might reflect
intrinsicdifferencesbetween theprofessions in termsof
attitudes to risk.
Meaning of the study
Rawlins and Culyer9 argue that the National Institute
forHealthandClinicalExcellencewouldbeunlikely to
reject a technology with a cost of between £5000 and
£15 000 per QALY. On the evidence of this trial,
therefore, doctor delivered endoscopy seems cost
effective.
Our economic analysis estimates the probability of
cost effectiveness from the uncertainty around the
estimates of costs and effects, rather than discarding
differences that do not reach “significance.”Hence this
methodological paradigm leads to a different inter-
pretation of our results from that adopted in the clinical
effectiveness paper.3
Classic statistical inference fails to reject the null
hypotheses that there is nodifference in effectivenessor
cost effectiveness between endoscopy delivered by
doctors and nurses. Policy makers might therefore
view nurse endoscopists as an acceptably safe and
effective way of changing skill mix in health care,
releasing medical resources and increasing the role of
nurse specialists. Bayesian analysis estimates the
probability that the intervention estimated cost per
QALYexceeds a given threshold.This formof analysis
leads to the conclusion that the average doctor endo-
scopist has a probability of 80-90% of being more cost
effective than the average nurse endoscopist at
commonly used values of willingness to pay for a
QALY. Decision makers pursuing efficiency alone
would therefore choose endoscopy delivered by
doctors.
Unanswered questions
The choice of skill mix in endoscopy might be
influenced by factors other than cost effectiveness,
such as affordability, staff shortages, and access to
health care. As nurses grow in experience over time it
will be important to continue to monitor both
effectiveness and cost effectiveness.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
To meet increasing demand for gastrointestinal endoscopy,
nurses are increasingly undertaking both upper and lower
endoscopy in the UK
Clinical studies,mainly observational and non-randomised,
have established the safety and acceptability of this, but
there has been little evaluation of the cost effectiveness
WHAT THIS PAPER ADDS
Though there is uncertainty around the results, doctors are
likely to be more cost effective than nurses for plausible
values of a QALY
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Association between change in high density lipoprotein
cholesterol and cardiovascular disease morbidity and
mortality: systematic review and meta-regression analysis
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ABSTRACT
Objective To investigate the association between
treatment induced change in high density lipoprotein
cholesterol and total death, coronary heart diseasedeath,
andcoronaryheartdiseaseevents (coronaryheartdisease
death and non-fatal myocardial infarction) adjusted for
changes in low density lipoprotein cholesterol and drug
class in randomised trials of lipidmodifying interventions.
DesignSystematic reviewandmeta-regressionanalysis of
randomised controlled trials.
Data sourcesMedline, Embase, Central, CINAHL, and
AMED to October 2006 supplemented by contact with
experts in the field.
Study selection In teams of two, reviewers independently
determinedeligibilityof randomised trials that tested lipid
modifying interventions to reduce cardiovascular risk,
reported high density lipoprotein cholesterol and
mortality or myocardial infarctions separately for
treatment groups, and treated and followed participants
for at least six months.
Data extraction and synthesis Using standardised, pre-
piloted forms, reviewers independently extracted relevant
information from each article. The change in lipid
concentrations for each trial and the weighted risk ratios
for clinical outcomes were calculated.
Results The meta-regression analysis included 108
randomised trials involving 299 310participants at risk of
cardiovascular events. All analyses that adjusted for
changes in low density lipoprotein cholesterol showed no
association between treatment induced change in high
density lipoprotein cholesterol and risk ratios for coronary
heart disease deaths, coronary heart disease events, or
total deaths. With all trials included, change in high
density lipoprotein cholesterol explained almost no
variability (<1%) in any of the outcomes. The change in the
quotient of low density lipoprotein cholesterol and high
density lipoprotein cholesterol did not explainmore of the
variability in any of the outcomes than did the change in
low density lipoprotein cholesterol alone. For a 10 mg/dl
(0.26 mmol/l) reduction in low density lipoprotein
cholesterol, the relative risk reduction was 7.2% (95%
confidence interval 3.1% to 11%; P=0.001) for coronary
heart disease deaths, 7.1% (4.5% to 9.8%; P<0.001) for
coronary heart disease events, and 4.4% (1.6% to 7.2%;
P=0.002) for total deaths, when adjusted for change in
high density lipoprotein cholesterol and drug class.
ConclusionsAvailabledatasuggest that simply increasing
the amount of circulating high density lipoprotein
cholesterol does not reduce the risk of coronary heart
disease events, coronary heart disease deaths, or total
deaths. The results support reduction in low density
lipoprotein cholesterol as the primary goal for lipid
modifying interventions.
INTRODUCTION
Large cohort studies have identified high density
lipoprotein cholesterol as a strong, independent,
inverse predictor of risk of coronary heart disease.1 2
This association, based on observational data, does not
establish the extent to which changes in high density
lipoprotein cholesterol will alter the risk of coronary
heart disease events.Many large randomised trials and
meta-analyses led to the identification of low density
lipoprotein cholesterol as the principal target for lipid
modifying interventions.34
Clinical trials of the high density lipoprotein raising
agent niacin have shown a reduction in coronary
events, but these trials either did notmeasure change in
high density lipoprotein cholesterol or failed to include
analyses adjusted for changes in low density lipopro-
tein cholesterol.5-9 Sub-studies of two trials using the
fibrate gemfibrozil suggested that an increase in high
density lipoprotein cholesterol reduces the risk of
coronary heart disease.10 11 However, new approaches
to increase high density lipoprotein cholesterol by the
cholesteryl ester transfer protein inhibitor torcetrapib
or by infusion of reconstituted high density lipoprotein
failed to show beneficial effects.12-15
We used meta-regression techniques in an updated,
comprehensive systematic review of randomised trials
to explore an independent link between changes in
high density lipoprotein cholesterol, covering all lipid
modifying treatment, and coronary heart disease
related morbidity and mortality.
METHODS
Data sources and searches
We included studies if they compared any lipid
modifying agent or diet with placebo or usual care or
compared a more intensive with a less intensive lipid
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modifying treatment; targeted reduction in cardio-
vascular risk; had a randomised control design;
reported mortality or myocardial infarctions; and
followedpatients for at least sixmonths.We excluded
studies that failed to report either change from
baseline or follow-up concentrations of high density
lipoprotein cholesterol and low density lipoprotein
cholesterol.
We searched Medline, Embase, Central, CINAHL,
and AMED. We reviewed reference lists of eligible
articles, editorials, and reviews and consulted with
experts.
Study selection and quality assessment
We assessed the methodological quality of eligible
studies by using the following criteria: concealment of
allocation; blinding of patients, caregivers, or clinical
outcome assessors; adherence to the intention to treat
principle; stopping early for benefit; and the propor-
tion of patients lost to follow-up.
Data extraction and end points
We recorded all baseline and follow-up concentrations
of total cholesterol, lowdensity lipoprotein cholesterol,
high density lipoprotein cholesterol, and triglycerides.
Clinical end points were total deaths, coronary heart
disease deaths, and coronary heart disease events
(combined outcome of non-fatal myocardial infarction
and coronary heart disease death).
Data synthesis and analysis
We calculated change in lipid concentrations for each
trial and pooled treatment effects across studies. We
used meta-regression analysis to investigate the asso-
ciation between differences in the change in high
density lipoprotein cholesterol and low density lipo-
protein cholesterol concentrations between treatment
and control groups and the risk ratios of clinical
outcomes of interest.16 To take into account non-lipid
effects of specific drugs, we included a variable of drug
class in the meta-regression model and did a meta-
regression analysis stratified by drug class. We
measured the proportion of the variability in the log
risk ratio of an outcome explained by the statistical
model (R2). We found little evidence for interactions
between change in high density lipoprotein cholesterol
and different classes of interventions (P=0.73), so we
omitted interaction terms.
In pre-specified sensitivity analyses, we focused on a
more homogeneous sample of trials that used inter-
ventions known to raise high density lipoprotein
cholesterol concentrations. In addition, we excluded
trials with agents that are associated with harmful
effects, such as torcetrapib or hormones. We did
further pre-specified sensitivity analyses excluding
trials with one year or less of follow-up or two years
or less of follow-up, as lipid effects may takemore than
a year to translate fully into clinical effects.17
RESULTS
Of 158 eligible randomised controlled trials, 50 did not
report change or follow-up values for both high density
lipoprotein cholesterol and low density lipoprotein
cholesterol and were excluded, leaving 108 trials for
analysis. In total, 146 890 participants were included in
the intervention groups and 152 520 in the control
groups. We classified trials according to 11 classes of
intervention (table 1).
Lipid modifying effects
Table 1 summarises the baseline concentrations and
changes in lipid subfractions for the different classes of
intervention. The averageweightedmean baseline low
density lipoprotein cholesterol concentration of all
included participants was 140 (SD 23; range 84-279)
mg/dl (3.62 mmol/l), and the high density lipoprotein
cholesterol concentration was 47 (7.4; 32-62) mg/dl
(1.22 mmol/l). The weighted mean change in low
Table 1 | Effects of different lipid modifying interventions on lipid subfractions. Values are weighted mean (SD) unless stated otherwise
Trials
No of
trials
No of
randomised
participants
Median
(interquartile
range) follow-
up (months)
Total cholesterol
(mg/dl)
LDL cholesterol
(mg/dl)
HDL cholesterol
(mg/dl)
Triglycerides
(mg/dl)
Baseline Change Baseline Change Baseline Change Baseline Change
All trials 111* 299 310 34 (24-54) 222 (23) −27 (22) 140 (23) −23 (19) 47.3 (7.4) 1.7 (3.1) 155 (19) −15 (18)
Statins 62 157 151 32 (24-51) 221 (25) −43 (15) 142 (24) −38 (13) 44.7 (5.5) 1.6 (1.5) 156 (18) −21 (9)
Fibrates 9 22 370 60 (55-60) 213 (32) −15 (7) 138 (29) −8.9 (6.7) 41.1 (4.9) 2.6 (2.3) 162 (16) −44 (14)
Resins 3 4005 60 (39-89) 280 (4) −23 (7) 206 (6) −25 (8) 44.2 (1.2) 2.7 (0.5) 155 (6) 6.1 (1)
Combinations
with niacin
6 779 27 (24-30) 231 (65) −41 (28) 156 (57) −42 (28) 39.9 (5.4) 12 (3.0) 166 (26) −48 (30)
n-3 fatty acids 9 13 768 24 (12-27) 216 (14) 1.1 (2.2) 142 (13) 7.6 (1.9) 41.8 (1.9) −0.1 (0.3) 166 (11) −12 (15)
Diet/surgery 5 62 645 78 (39-97) 228 (7) −4.0 (6) 139 (10) −6.4 (8.4) 55.5 (7.2) −0.1 (0.4) 152 (23) 0.8 (5)
ACAT inhibitors 2 717 12 (6-18) 179 −23 106 −2.1 42.5 −0.3 156 −10
Probucol 2 481 16 (7-24) 242 −31 160 −19 48.2 −12.3 171 1.1
Glitazones 2 9589 42 (36-48) 204 NA 116 3.6 44.5 3.1 162 −15
Hormones 9 25 710 38 (24-49) 226 (6) −2.4 (1.4) 132 (9) −13 (5) 53.1 (2.3) 4.3 (3.1) 148 (17) 26 (11)
Torcetrapib
(+ statin)
2 2095 24 (24-24) 182 5.1 107 −21 48.5 27.7 112 −6.2
ACAT=acyl-CoA:cholesterol acyltransferase; HDL=high density lipoprotein; LDL=low density lipoprotein; NA=not available.
*Includes three studies with three trial arms; excludes one study that did not report baseline values (only change during follow-up).
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density lipoprotein cholesterol was −23 (SD 19) mg/dl
(−0.59mmol/l), and theweightedmean change in high
density lipoprotein cholesterol was 1.7 (3.1) mg/dl
(0.04 mmol/l). Almost all classes of intervention
reduced low density lipoprotein cholesterol except
for n-3 fatty acids and glitazones. High density
lipoprotein cholesterol was raised by most classes of
intervention except for n-3 fatty acids, low-fat diets,
acyl-CoA:cholesterol acyltransferase inhibitors, and
probucol. In addition, high dose statin treatment
slightly reduced high density lipoprotein cholesterol
compared with less intensive statin treatment
(weighted mean change −0.23 (SD 0.83) mg/dl),
w56-w59 w61 w62 whereas statins overall raised it moder-
ately (weighted mean change 1.6 (1.5) mg/dl).
Meta-regression analysis for clinical outcomes
Change in low density lipoprotein cholesterol was
associated with and explained a statistically significant
degree of variability in the log risk ratio for coronary
heart disease events, coronary heart disease death, and
total death in univariable and multivariable meta-
regression analysis adjusted for change in high density
lipoprotein cholesterol and different drug classes
(table 2).Change in lowdensity lipoprotein cholesterol
explained 32% of the variability in the log risk ratio for
coronary heart disease events (see R2 for univariable
model with low density lipoprotein cholesterol in
table 2).
We foundnosignificant associationof change inhigh
density lipoprotein cholesterol with the log risk ratio in
any model after adjustment for changes in low density
lipoprotein cholesterol (see table 2). Change in high
density lipoprotein cholesterol hardly explained any
variability in any of the outcomes (see R2 results in
table 2). The change in the quotient of low density
lipoprotein cholesterol and high density lipoprotein
cholesterol explained 32%, 12%, and 15% of the
variability in log risk ratios for coronary heart disease
events, total death, and coronary heart disease death,
which is no more than the change in low density
lipoprotein cholesterol alone explained for these out-
comes (see R2 results for univariable models with low
density lipoprotein cholesterol in table 2).
Sensitivity analyses focusing on a more homoge-
neous sample of trials revealed a significant association
of change in high density lipoprotein cholesterol and
the log risk ratio for coronary heart disease events in
univariable analysis, with a 29% (51.7% to 6.6%;
P=0.01) risk reduction for each 10 mg/dl increase in
high density lipoprotein cholesterol. This association
was, however, no longer detectable in models adjusted
for changes in low density lipoprotein cholesterol
(bivariable or multivariable). Change in low density
lipoprotein cholesterol remained significantly asso-
ciated with the log risk ratio for coronary heart disease
events, explaining greater variability in trials that had
longer follow-up (R2 of 0.41, 0.46, and 0.51 for trials
with a follow-up of six months or more, more than one
year, and more than two years).
DISCUSSION
This systematic review andmeta-regression analysis of
108 randomised controlled trials using lipidmodifying
interventions did not show an association between
treatmentmediated change in high density lipoprotein
cholesterol and risk ratios for coronary heart disease
events, coronary heart disease deaths, or total deaths
whenever change in low density lipoprotein choles-
terol was taken into account. We found a statistically
significant, substantial association between change in
low density lipoprotein cholesterol and risk ratios for
coronary heart disease events, coronary heart disease
deaths, or total deaths, adjusted for other lipid
subfractions and drug class. Our results indicate a 7%
relative risk reduction in coronary heart disease events
for every 10 mg/dl (0.26 mmol/l) reduction in low
density lipoprotein cholesterol,which is equivalent to a
10%relative reduction in coronaryheart disease events
for every 10% decrease in low density lipoprotein
Table 2 | Meta-regression models investigating association of change in HDL cholesterol, LDL
cholesterol, or both with log risk ratios of clinical outcomes
Regression model and
predictor
Change in risk per 10 mg/dl increase in lipid
subfraction—% (95% CI) P value R2*
CHD events (CHD death and non-fatal MI) (n=95)†
Univariable:
Change in LDL 4.9 (3.4 to 6.5) <0.001 0.32
Change in HDL −8.2 (−24.7 to 8.1) 0.32 0.01
Bivariable:
Change in LDL 5.1 (3.6 to 6.7) <0.001
0.33
Change in HDL 6.4 (−7.8 to 20.4) 0.37
Multivariable‡:
Change in LDL 7.1 (4.5 to 9.8) <0.001
0.46
Change in HDL 16.0 (−4.2 to 36.9) 0.12
Total death (n=107)†
Univariable:
Change in LDL 2.8 (1.4 to 4.3) <0.001 0.12
Change in HDL 5.5 (−8.5 to 19.2) 0.44 0.01
Bivariable:
Change in LDL 3.1 (1.7 to 4.6) <0.001
0.15
Change in HDL 12.1 (−1.1 to 25.2) 0.07
Multivariable‡:
Change in LDL 4.4 (1.6 to 7.2) 0.002
0.28
Change in HDL 11.0 (−6.5 to 28.1) 0.21
CHD death (n=94)†
Univariable:
Change in LDL 4.5 (2.4 to 6.6) <0.001 0.16
Change in HDL −0.2 (−24.0 to 23.1) 0.99 <0.01
Bivariable:
Change in LDL 4.8 (2.6 to 7.0) <0.001
0.17
Change in HDL 11.3 (−10.8 to 32.9) 0.31
Multivariable‡:
Change in LDL 7.2 (3.1 to 11.3) 0.001
0.33
Change in HDL 12.2 (−18.0 to 41.5) 0.42
CHD=coronary heart disease; HDL=high density lipoprotein; LDL=low density lipoprotein; MI=myocardial
infarction.
*Proportion of total variability in log risk ratio of outcome explained by model.
†Absence of outcome events in intervention and control groups or absence of reporting this outcome event led
to reduced sample of trials.
‡Models include adjustment for drug class in addition to variables of lipid subfractions.
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cholesterol; this is consistent with the magnitude of
reduction reported in current National Cholesterol
Education Program guidelines.3
Strengths and limitations
Strengths of this study include a comprehensive scope
that included a wide range of patients at risk of
cardiovascular events and a wide variety of lipid
modifying interventions. Our extensive literature
search supplemented by contacting experts in the
field minimised the potential for publication bias, but
we cannot exclude it completely.We could not include
50 trials that failed to report follow-up values or change
in low density lipoprotein cholesterol or high density
lipoprotein cholesterol.
To limit the risk of data driven spurious associations
and overfitting, we pre-specified a limited number of
predictors for our statistical models.18 Our results
proved robust in pre-specified sensitivity analyses and
were consistent with other investigations that have
examined similar data.3 Our systematic review is far
more comprehensive than previous studies on this
subject.19 Nevertheless, the relation described by a
meta-regression is observational—a meta-regression
across trials does not have the benefit of randomisation
to support a causal interpretation and thus risks bias by
confounding.
Our classification of lipid modifying interventions
may be argued to combine antilipidaemic agents and
diets that have important pharmacological differences
or mechanisms of action.20 Different interventions that
alter high density lipoprotein cholesterol may have
different impacts on cardiovascular risk. Our adjust-
ment of the analysis by type of intervention (drug class)
deals with this problem to a considerable extent but
may not fully solve it.
Finally, meta-regression relies on aggregated data
from studies rather than data from individual patients.
Ideallyour resultswouldbeconfirmedbyananalysis of
data from individual patients, with a large pooled
dataset of trials.
New views on high density lipoprotein cholesterol
Our findings contribute to accumulating evidence that
simply increasing the amount of circulating high
density lipoprotein cholesterol does not necessarily
confer cardiovascular benefits.12-15 21 In the case of
torcetrapib, the failure to improve intracoronary
atheroma burden in ultrasound studies and the excess
mortality seen in the ILLUMINATE trial may be
explained by a molecule specific increase in blood
pressure or unforeseen interactions between torcetra-
pib and atorvastatin.12 13 15 22 Recent data suggest the
former possibility23; if so, other cholesteryl ester
transfer protein inhibitors may still hold promise.
An alternative hypothesis would suggest that inhibi-
tion of the cholesteryl ester transfer protein leads to
production of dysfunctional high density lipoprotein
cholesterol with pro-inflammatory and atherogenic
properties.24 Lipid modifying agents and diets may
affect the functionality of high density lipoprotein
cholesterol.
Implications for clinical practice and future research
Our findings raise questions about the rationale for
developing therapeutic agents that increase high
density lipoprotein cholesterol without considering
effects on its function. Future research should pro-
spectively consider the resultsof assays tomeasurehigh
density lipoprotein function and then provide defini-
tive evidence of pharmacological effects on patient
important outcomes in long term randomised trials.25
Results from this study corroborate recommendations
from current clinical guidelines that emphasise target-
ing primarily low density lipoprotein cholesterol in the
prevention of cardiovascular morbidity and
mortality.3 4 26
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cardiovascular risk factor
The extent towhich changes in high density lipoprotein cholesterol alter risk of coronary heart
disease events remains controversial
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No association exists between treatment induced change in high density lipoprotein
cholesterol and risk ratios for coronaryheart disease events, coronaryheart diseasedeaths, or
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Whereaschange inhighdensity lipoproteincholesterol failedtoexplainvariability in risk ratios
for coronaryheart diseaseeventsacrossstudies, change in lowdensity lipoprotein cholesterol
explained about one third of the variability
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ABSTRACT
Objectives To examine the care experiences of South
Asian Sikh and Muslim patients in Scotland with life
limiting illness and their families and to understand the
reasons for any difficulties with access to services and
how these might be overcome.
DesignProspective, longitudinal, qualitative design using
in-depth interviews.
Setting Central Scotland.
Participants 25 purposively selected South Asian Sikh
and Muslim patients, 18 family carers, and 20 key health
professionals.
Results 92 interviews took place. Most services
struggled to deliver responsive, culturally appropriate
care. Barriers to accessing effective end of life care
included resource constrained services; institutional
and, occasionally, personal racial and religious
discrimination; limited awareness and understanding
among South Asian people of the role of hospices; and
difficulty discussing death. The most vulnerable
patients, including recentmigrants and thosewith poor
English language skills, with no family advocate, and
dying of non-malignant diseases were at particularly
high risk of inadequate care.
Conclusions Despite a robust Scottish diversity policy,
services for South Asian Sikh and Muslim patients with
life limiting illness were wanting in many key areas.
Active case management of the most vulnerable
patients and carers, and “real time” support, from
where professionals can obtain advice specific to an
individual patient and family, are the approaches most
likely to instigate noticeable improvements in access to
high quality end of life care. Improving access to
palliative care for all, particularly those with non-
malignant illnesses, as well as focusing on the specific
needs of ethnic minority groups, is required.
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INTRODUCTION
In palliative care the notion of a good death is based on
patients being fully aware of their diagnosis and
prognosis and able to engage in advance care planning.
This does not, however, necessarily reflect different
social, cultural, and spiritual beliefs and practices
around death and dying.1 We studied the care
experiences of South Asian Sikh and Muslim patients
with life limiting illness and of their families from the
perspectives of the patient, family carer, and health
professionals.
METHODS
We purposively recruited South Asian Sikh and
Muslim patients with life limiting conditions with a
prognosis of less than a year. Definitions for ethnicity,
race, faiths, and languages of participants are on
bmj.com. The researchers approached health profes-
sionals, community and religious leaders, and volun-
teer workers to identify eligible individuals. They then
gave an information sheet about the project to the
potential participant in English as well as in Gurumu-
khi or Urdu. The trilingual researcher (TI) explained
the study and obtained written consent. Patients were
asked to nominate a family carer and the health
professional most involved in their care.
TI interviewed thepatients and family carers,mainly
at home, and professionals were also interviewed,
mainly by telephone. Up to three in-depth, semistruc-
tured interviews (see bmj.com) were carried out with
each participant over 18 months. If appropriate,
interviews were carried out with family and profes-
sional carers 8-12weeks after death.A researcher and a
trilingual secretary recorded, transcribed, and trans-
lated the interviews when necessary; to ensure
contextual accuracy translated transcripts were
checked against recorded interviews.
Analysis was ongoing to allow emerging themes to
be fed back into subsequent interviews. Constant
comparison ensured that the thematic analysis
approach represented all perspectives.2 3 Each inter-
view was analysed individually and compared with
earlier or subsequent interviews to determine how
needs and service use changed over time.
RESULTS
In all, 25 people with life limiting illness (seven Sikh
patients and 18 Muslim patients), 18 carers, and 20
health professionals participated. Ninety two inter-
views took place. Eleven patients had cancer, 14 other
long term illnesses. Participants were younger (mean
age 59 (SD14.7) years) than those typically recruited in
end of life studies4 5 and had younger families. Most
lived in nuclear or extended families and three lived
alone. Six patients died during the study. The family
carers were predominantly women, along with four
husbands andone son (see bmj.com). Fourpatients had
no family carer and three carers declined to participate.
Among the range of professionals nominated, most
(n=13) were general practitioners (see bmj.com).
The experiences of the patients and their families
were, in many respects, similar to those identified in
other end of life studies in the general population (see
bmj.com for overlapping themes).4-7 The box sum-
marises the experiences more evident in the partici-
pants in this study.
Accessing effective end of life care
Only twopatients, bothwith cancer, accessedpalliative
care services.Theydied inahospice,where thepatients
and their carers reported that staff showed exceptional
willingness to learn about and meet their particular
needs:
“This hospice has been very good to us. They’ve said if
there’s anything you need, tell us. They’ve gone out
and got halal meat. Anything we’ve wanted, they’ve
gone and got.” (Carer 20, wife of Muslim patient with
cancer, stage 1 interview)
Two other patients who were not yet terminally ill
reported coordinated andwell managed palliative care
(see bmj.com). Both were highly articulate, assertive,
knowledgeable about services, and took a leading role
in determining the course of their treatment and the
services they received.
Barriers to effective end of life care
Many patients, particularly those with non-cancer
illness, did not seem to receive care based on manage-
ment of a long term condition or palliative care. It was
evident from the responses of patients, carers, and
professionals that the barriers to accessing end of life
care arose from the perceptions and beliefs of ethnic
minority communities about death and dying and end
of life care, the inflexibility of services, and the attitudes
of service providers.
Barriers among patients and families
Planning effective end of life care was difficult when
there was a lack of open discussion about dying (see
bmj.com for a list of barriers). Families sometimes
controlled information, especially when acting as
interpreters for health professionals. For example, a
woman acting as interpreter for her husband did not
want hospice staff to discuss his poor prognosis,
whereas it was apparent from interviewing the patient
that he had a clearer idea:
“I said to them ‘don’t tell himhow long,’but they said if
he asks anyquestions, they’ll have to tell him.Henever
asked.” (Carer 20, wife of Muslim patient with cancer,
stage 1 interview)
In a separate interview, the patient said:
“Everything is finishing now, nothing works . . .
[crying]. I don’t know what to do. I’ve got five
daughters, who is going to provide for them? I don’t
know what to do. What will they do? There is nothing
else they [the hospice] can do—no cure.” (Patient 20,
Muslim man with cancer, stage 1 interview)
RESEARCH
BMJ | 28 FEBRUARY 2009 | VOLUME 338 527
Other patients perceived the hospice as “somewhere
to go to die.” While not unusual in the general
population, this view was widespread among patients
and carers in our study, with the perception of cultural
inappropriateness presenting an additional barrier.
A fewpatients found it challenging toacceptpersonal
care from non-Asian caregivers; concerns were
expressed about privacy and cultural misunderstand-
ings. Prejudices about standards of behaviour and
cleanliness of white people were also apparent:
“Iwill never allow them to domy cooking . . .Wedon’t
even knowwhat they’ve eaten before they came to see
me, or even if they’vewashed their hands after theyuse
the toilet . . . how can we rely on them?” (Patient 18,
Muslim woman with non-malignant illness, stage 1
interview)
Patients and families sometimes perceived prejudice
from service providers:
“The nurses get angry at me . . . I don’t know whether
they treat our people that way or if it’s everyone.”
(Carer 8, daughter ofMuslimmanwith non-malignant
illness, stage 2 interview)
Perceived discrimination by service providers and
concern about what others in their own community
would say contributed to reluctance to seek help.
Inability to speak English was perceived as a major
disadvantage in accessing services, forming relation-
ships with professionals, and negotiating care options.
It also meant that bereavement could be a particularly
isolating experience for carers.
Barriers among professionals
The barriers among professionals are listed on
bmj.com. The low number of patients from ethnic
minority groups accessing palliative care was recog-
nised but not well understood:
“I would like to see them [Asian patients] being
referred to us more often and I don’t understand why
they are not. There must be many more patients out
there.” (Patient 1, health professional interview)
Most professionals expressed good intentions in
striving to provide equitable care but were concerned
by their lack of cultural understanding and uncertain
about how to adapt their usual care. Other profes-
sionals were anxious about making a cultural blunder.
A lack of understanding and awareness of cultural
needs was acknowledged:
“Not knowing much about the religion . . . that is
sometimes difficult because you don’t really know
what you are talking about . . . maybe if I had known
more about that then I could have been more help to
him.” (Carer 20 , interview with professional after
death)
Many professionals interviewed were unaware of
any training in diversity and cultural awareness, and
others suggested that existing approaches were ineffec-
tive in changing services and attitudes:
“There are things that are supposed to be happening in
relation to Fair for All, equality and diversity, all these
fine words, but you do begin to wonder, it is fine
rhetoric and nobody is disagreeing with it, but on the
shop floor it is not making a huge amount of
difference.” (Patient 6, interview with professional)
Institutional discrimination also created a barrier.
Services often had difficulty managing basic needs such
as communication with non-English speakers, diet, and
hygiene. At times care was clearly culturally insensitive:
“There were only twomales in the department sowhat
do you do then? [sounding anxious] I had to get help
but they said ‘wewon’t look’but look isnot everything,
you can feel aswell.What organs is where, what part of
your body, he just has to visualise it, don’t have to
look.” (Patient 4, Muslim woman with non-malignant
illness, stage 2 interview)
Trying to organise interpreters at short notice was
seen by service providers as impossible. In some cases
the patient was required to be the translator.
Services were often reactive rather than based on
needs, with little flexibility about timing or roles. They
therefore struggled tomeet complex or variable needs.
Constraintson resourceswereobvious, and relianceon
family carers was acknowledged.
Overcoming barriers: an illustration of discrimination and
effective advocacy
A Sikh patient with long term conditions, who was
homeless and an asylum seeker, complained of
hostility from staff, neglect of his needs, inappropriate
food, and feelinghumiliated if he complainedabout the
food or asked about his treatment:
“Oneof thenurses said tome that ‘Iwill paint ahorrible
picture of you and report you to the immigration and
they will deport you,’ that’s how they treat me.”
(Patient 6, Sikhmanwith non-malignant illness, stage 1
interview)
The professional interviewed confirmed that his care
had been poor:
“It did appear to me that some of the clinicians and
managers who had a clinical background, in my view
probably should have known better, seemed to be
suggesting that they send him back to [own country] as
soon as they possibly could, apparently without any
notion of the consequences.” (Patient 6, interviewwith
professional]
The professional adopted an advocacy role for the
patient’s needs, addressed his diet, helped him access
benefits, and liaised with staff on his behalf. His care
was taken over by a different clinical team, with whom
he had good relationships.
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Vulnerability
It was apparent that the most assertive patients and
families, articulate in English, and those with a good
advocate were able to access services more effectively
than those who were less able to assert their needs. In
contrast we found that recent migrants and those with
poor English, no family advocate, and dying of non-
malignant diseases were less able to articulate their
needs and negotiate care.
DISCUSSION
This study has found that end of life care remains
substandard for many South Asian Sikh and Muslim
patients, particularly the most vulnerable. Exploring
the end of life needs of ethnic minority and faith
communities qualitatively over time from patient,
family carer, and professional perspectives offers
important new insights. Previous studies have found
that palliative care services are not culturally
sensitive.8 9 The risk of cultural misunderstandings
around end of life care may grow with increasing
heterogeneity of ethnic and religious groups.10
Feelings of exclusion from mainstream society and
services are an additional previously unrecognised
barrier to access.11 Services were often inflexible and
unable to respond effectively when faced with “atypi-
cal” needs. This resulted in patients and carers
perceiving themselves as being discriminated against
and treated with a lack of respect and dignity. The
recent Darzi report emphasised the core requirement
for high quality, personalised services, with particular
care needed for those least likely to seek help because
they feel discriminated against.12 Our study showed
that it is possible for existing services to provide good
end of life care for such patients and families—this was
particularly evident in hospices and someprimary care
services where the key component was an individua-
lised approach to end of life care.
The barriers to accessing the best quality care were
complex and apparent in the cultural perceptions of
patients and families as well as constraints on services.
These could, however, be overcome by effective
advocacy from service providers. Although a hospice
wasperceivedbysomeSouthAsianpeople inour study
as a potentially alienating experience, the care received
by two patients suggests that hospices can provide
culturally sensitive care. Responsibilities also lie with
South Asian communities being open to accepting
help.
Equitable access to culturally competent services for
all ethnic groups is a Scottish health policy
requirement13 that has resulted in increased awareness
among service providers of the needs of ethnic
minorities. Our study shows that this has not necessa-
rily led to development of the structures or skills that
will enable professionals to deliver culturally appro-
priate end of life care. Effective practice can be
hampered by uncertainty, hesitancy, and inertia in
the face of worries about cultural competence, possibly
contributing to institutional racism.14 Health profes-
sionals can be distressed by their (perceived or actual)
inability to provide good care for people from ethnic
minority groups.15 Professionals in our study stressed
their desire to deliver culturally competent care, but
also expressed uncertainties about cultural aspects of
complex end of life care. Our experiences suggest that
“real time” advice on appropriate responses, where
professionals could discuss an individual patient at the
time they are providing care, would be helpful in
building the skills and confidence to deliver culturally
sensitive palliative care.
Equitable access to appropriate end of life care is not
merely an issue for people fromethnicminority groups
and different faith backgrounds. People from ethnic
Main themes more evident in the South Asian population
than general population
Faith and coping
 Illness and suffering viewed as God’s will and a test of
faith
 Struggle to reconcile present suffering with the
promise of a good afterlife
 God’s approval sought through positive thinking and
actions
 Despair and anger seen as spiritual deficits and
thereforeemotionalproblemsdifficult toacknowledge
openly
Death and dying
 Less open discussion of death and dying within
families, even among patients with cancer
 Hospices perceived as culturally inappropriate for
South Asian people
Service provision
 Basic needs, such as culturally acceptable food and
culturally sensitive personal care, not always met by
services
 Institutional or overt personal racism sometimes
apparent in patients’ and carers’ interactions with
services
 Poor service provision sometimes perceived as
racially-motivatedwhere therewas little evidence that
this was the case
 Somepatientsandfamilieswere reluctant toseekhelp
fromservices theyperceived as racist, or because they
had poor experience of services, or were concerned
about criticism from own community
 Inadequate professional training in diversity and
concernabout causingoffence through lackof cultural
understanding
 Somestaff awarenessof theneedsofSikhandMuslim
patients but uncertainties about how to adapt usual
care to a different cultural context
 Professionals uncertain about accurate, complete,
and effective communication when patients or family
members acted as interpreters
 Specialist palliative care accessed by few patients,
even those with cancer
 Exceptional willingness and adaptability of hospice
staff to meet the needs of Sikh and Muslim patients
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minority groupsmay perceive inadequacies in services
as based on racism when the problem is a generally
poor service. Improving access to palliative care for all
—particularly thosewith non-malignant illnesses—and
focusingon the specificneedsof ethnicminoritygroups
is therefore required.
Strengths and limitations
Our theoretically informed approach, enhanced by
interviewing patients, carers, and key professionals,
enabled us to gain insights that would have been
unavailable through single interviews—for example,
the experiences of the Sikh man whose care was
improved by a professional adopting an advocacy role.
The methodological approach also enabled us to
identify the direct, rather than perceived, discrimina-
tion this case exemplifies, by interviewing the key
professional. Additional strengths include the high
proportion of participants that agreed to participate
(96%) and the high retention rate, with most attrition
occurring because of death.
Recognising vulnerability
Thepremise that ethnicminority groups have the same
needs as the rest of the population is too simplistic.
Vulnerability leads to greater risk of poor health and
poorer access to services. Prioritising the needs of the
most vulnerable patients and carers might be a
particularly effective way of reducing inequalities.
Our data suggest that trigger factors for recognising
vulnerability in patients with advanced illness include
social deprivation, insufficient English, non-cancer
illness, multiple comorbidities, lack of support from
the family and community, and new migrants and
those with uncertain legal status, such as asylum
seekers.
Implications for policy, practice, and research
Improving care for ethnic minority groups involves
partnership working where professionals are able to
recognise their lack of knowledge and expertise in
cultural practices and take advice from patients,
families, and community groups. Active outreach and
community development with South Asian commu-
nities should help to raise awareness and overcome
misconceptions of palliative and hospice care.
Involving patients and members of communities in
the delivery, evaluation, and support of professional
training is important. In UK primary care, points from
the quality outcomes framework (and hence reimbur-
sement) are now available for significant event
analysis,16 where care teams are encouraged to reflect
on real cases and to identify strengths and weaknesses
in care provided. This could be adapted to diversity
training. Resources are available to support clinicians
and educators in developing cultural competence
(www.library.nhs.uk/ethnicity).1 9 17 18
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WHAT IS ALREADY KNOWN ON THIS TOPIC
People from ethnic minority groups are less likely to access
palliative care services than the majority population
Barriers to access include attitudes of the patient, family,
and professionals
End of life needs in minority groups are poorly understood
WHAT THIS STUDY ADDS
Within ethnic minority groups the most vulnerable people,
suchas recentmigrants, have the poorest access to services
Active casemanagement of high riskpatients shouldhelp to
overcome many of these barriers
Professionals need ready access to information and support
specific to an individual patient and family
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means 5.04). Study size was not associated with 
concordance, content of take home message, funding, 
or study quality. Higher citation index factor was 
associated with partial or complete industry funding.
Bias, confounding, and other reasons for caution
The association between higher citation index factor 
and funder was sensitive to the exclusion from the 
analysis of studies with undeclared funding. These 
comprised 23% of the population (64/274). 
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selection criteria for studies
We searched the Cochrane Library, PubMed, Embase, 
and the internet, without language restriction, for any 
studies comparing the population effects of influenza 
vaccines against placebo or no intervention. 
Primary outcome(s)
Methodological quality, concordance (agreement 
between data presented and conclusions), impact, and 
citation of included studies in relation to funding.
Main results and role of chance
Higher quality studies were significantly more likely 
to show concordance between data presented and 
conclusions (odds ratio 16.35, 95% confidence interval 
4.24 to 63.04) and less likely to favour effectiveness 
of vaccines (0.04, 0.02 to 0.09). Government funded 
studies were less likely to have conclusions favouring 
the vaccines (0.45, 0.26 to 0.90). A higher mean journal 
impact factor was associated with complete or partial 
industry funding compared with government or 
private funding and no funding (differences between 
Study queStion What is the relation between study 
concordance, take home message, funding, and 
citation (as a proxy for dissemination) in 274 studies 
on influenza vaccines?
Summary anSwer Influenza vaccines studies 
have poor methodological quality. There are 
discrepancies between results and conclusions, but 
these are overwhelmingly favourable. Publication in 
prestigious journals and higher citation is associated 
with partial or total industry funding, but this is not 
due to study quality or size.
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  with its quality
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